Rheumatology Clinic, St. Joseph's Health Care
London, Ontario, N6A 4V2, Canada
NCT Number: NCT03889509
This protocol is of a systematic review for risk factors of pulmonary arterial hypertension in systemic sclerosis.
Looking for future studies?
Notify MeAll sexes
Observational
London, Ontario, N6A 4V2, Canada
A systematic review was conducted to determine the risk/associated factors for pulmonary arterial hypertension in systemic sclerosis, including clinical/disease characteristics, antibody status, test results and biomarkers. The frequency of publications featuring a risk/association were reported. The following databases were searched: Medline, EMBASE, the Cochrane Library, Web of Science, and SCOPUS.
The following search terms were used:
( essential pulmonary hypertension or familial primary pulmonary hypertension or hypertension, pulmonary or hypertension,lung or hypertensive pulmonary vascular disease or idiopathic pulmonary arterial hypertension or lung arterial hypertension or lung artery hypertension or lung hypertension or primary pulmonary hypertension or pulmonary arterial hypertension or pulmonary artery hypertension or pulmonary fixed hypertension or pulmonary hypertensive disease or pulmonary hypertensive diseases or pulmonary hypertensive disorder or pulmonary hypertensive disorders )
AND
( generalised scleroderma or generalized scleroderma or progressive scleroderma or progressive sclerodermia or progressive sclerosis,systemic or progressive systemic sclerosis or scleroderma, generalised or scleroderma, generalized or scleroderma, progressive or scleroderma, systemic or sclerosis,progressive systemic or sclerosis,systemic or sclerosis,systemic progressive or systemic progressive sclerosis or systemic scleroderma or systemic sclerosis,progressive or
scleroderma, limited or limited scleroderma or limited cutaneous scleroderma or
diffuse scleroderma or progressive diffuse scleroderma or scleroderma, diffuse )
AND
( prevalence or prevalence study or relative risk or risk factors )
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years from study start date
to determine the prevalence associated with pulmonary arterial hypertension in scleroderma
Time frame: 2 years from study start date
to determine the risk factors associated with pulmonary arterial hypertension in scleroderma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00377949
Cardiovascular Diseases, Connective Tissue Diseases
Los Angeles, California, United States
View Trial DetailsNCT01042158
Cardiovascular Diseases, Connective Tissue Disease
Baltimore, Maryland, United States
View Trial DetailsNCT01208792
Acquired Immunodeficiency Syndrome, Arthritis
Clamart, France
View Trial DetailsNCT07717060
Connective Tissue Diseases, Digital Ulcers
View Trial Details